Table 1. The relationship between GIT1 expression and the clinicopathological characteristics of Non-Small Cell Lung Cancer (NSCLC) in training cohort.
| Clinicopathological Characteristics | n | GIT1 expression, n (%) | Pa | |
|---|---|---|---|---|
| Low (n = 47) | High (n = 78) | |||
| Age | ||||
| <65 y | 73 | 26 (35.6%) | 47 (64.4%) | 0.587 |
| ≥65 y | 52 | 21 (40.7%) | 31 (59.3%) | |
| Gender | ||||
| Male | 71 | 25 (35.2%) | 46 (64.8%) | 0.527 |
| Female | 54 | 22 (40.7%) | 32 (59.3%) | |
| Smoking | ||||
| Smoker | 50 | 17 (34.0%) | 33 (66.0%) | 0.497 |
| Non-smoker | 75 | 30 (40.0%) | 45 (60.0%) | |
| Histology | ||||
| Adenocarcinoma | 81 | 34 (42.0%) | 47 (58.0%) | 0.367 |
| Squamous cell carcinoma | 35 | 10 (28.6%) | 25 (71.4%) | |
| Adenosquamous carcinoma | 2 | 0 (0%) | 2 (100%) | |
| Large cell carcinoma | 7 | 3 (42.9%) | 4 (57.1%) | |
| T stageb | ||||
| T1+T2 | 89 | 32 (36.0%) | 57 (64.0%) | 0.551 |
| T3+T4 | 36 | 15 (41.7%) | 21 (58.3%) | |
| N stageb | ||||
| N0 | 48 | 24 (50.0%) | 24 (50.0%) | 0.023 |
| N1–3 | 77 | 23 (29.9%) | 54 (70.1%) | |
| M stageb | ||||
| M0 | 89 | 34 (38.2%) | 55 (61.8%) | 0.827 |
| M1 | 36 | 13 (33.3%) | 23 (66.7%) | |
| Pathological stageb | ||||
| I, II | 53 | 23 (43.4%) | 30 (56.6%) | 0.251 |
| III, IV | 72 | 24 (37.7%) | 48 (62.3%) | |
| Recurrence | ||||
| No | 32 | 17 (53.1%) | 15 (46.9%) | 0.036 |
| Yes | 93 | 30 (32.3%) | 63 (67.7%) | |
| Grade | ||||
| I, II | 95 | 38 (40.0%) | 57 (60.0%) | 0.324 |
| III | 30 | 9 (30%) | 21 (70%) | |
a
P values were derived with a two-sided Pearson chi-square test. SD represents standard deviation.
b
Tumor stage, lymph node status, and metastasis status were classified in accordance with the international system for staging lung cancer.